» Articles » PMID: 39177798

Adding Hetrombopag to Cyclosporine a Improved Response of Patients with Newly Diagnosed Transfusion-dependent Non-severe Aplastic Anemia

Overview
Journal Ann Hematol
Specialty Hematology
Date 2024 Aug 23
PMID 39177798
Authors
Affiliations
Soon will be listed here.
References
1.
Marsh J, Ball S, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith E . Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009; 147(1):43-70. DOI: 10.1111/j.1365-2141.2009.07842.x. View

2.
Nishio N, Yagasaki H, Takahashi Y, Muramatsu H, Hama A, Yoshida N . Natural history of transfusion-independent non-severe aplastic anemia in children. Int J Hematol. 2009; 89(4):409-413. DOI: 10.1007/s12185-009-0302-9. View

3.
Syed Y . Hetrombopag: First Approval. Drugs. 2021; 81(13):1581-1585. DOI: 10.1007/s40265-021-01575-1. View

4.
Peng G, He G, Chang H, Gao S, Liu X, Chen T . A multicenter phase II study on the efficacy and safety of hetrombopag in patients with severe aplastic anemia refractory to immunosuppressive therapy. Ther Adv Hematol. 2022; 13:20406207221085197. PMC: 8972928. DOI: 10.1177/20406207221085197. View